Repligen Corporation $RGEN Shares Sold by Assenagon Asset Management S.A.

Repligen logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Assenagon Asset Management cut its Repligen stake by 97.9% in the third quarter, selling 69,506 shares and retaining 1,489 shares valued at approximately $286,000.
  • Institutional investors and hedge funds own 97.64% of Repligen’s shares, while several major firms recently initiated positions in the biotechnology company.
  • Analysts remain broadly bullish, with a “Moderate Buy” consensus and an average price target of $175.71; Repligen’s latest quarterly results also exceeded EPS and revenue expectations.
  • Five stocks to consider instead of Repligen.

Assenagon Asset Management S.A. trimmed its position in Repligen Corporation (NASDAQ:RGEN - Free Report) by 97.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,489 shares of the biotechnology company's stock after selling 69,506 shares during the period. Assenagon Asset Management S.A.'s holdings in Repligen were worth $286,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. United Capital Financial Advisors LLC purchased a new stake in shares of Repligen during the second quarter valued at approximately $380,756,000. Maverick Capital Ltd. purchased a new stake in Repligen during the 1st quarter worth $178,946,000. Wasatch Advisors LP purchased a new stake in Repligen during the 1st quarter worth $146,513,000. William Blair Investment Management LLC acquired a new position in Repligen in the 2nd quarter worth $107,593,000. Finally, Bamco Inc. NY acquired a new position in Repligen in the 2nd quarter worth $102,121,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on RGEN. UBS Group reaffirmed a "buy" rating on shares of Repligen in a research report on Tuesday, September 29th. Citigroup raised shares of Repligen to a "buy" rating in a research report on Tuesday, July 7th. Barclays boosted their price objective on Repligen from $175.00 to $225.00 and gave the company an "overweight" rating in a report on Wednesday, October 7th. Benchmark upgraded Repligen from a "hold" rating to a "buy" rating and set a $185.00 price objective on the stock in a research note on Tuesday, July 7th. Finally, JPMorgan Chase & Co. increased their target price on Repligen from $165.00 to $175.00 and gave the stock an "overweight" rating in a report on Wednesday, July 29th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $175.71.

View Our Latest Stock Report on Repligen

Repligen Stock Performance

RGEN stock opened at $176.93 on Friday. The company has a 50-day simple moving average of $177.12 and a 200 day simple moving average of $147.67. The company has a market capitalization of $9.99 billion, a P/E ratio of 242.37, a PEG ratio of 3.26 and a beta of 1.08. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $198.87. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company had revenue of $204.13 million for the quarter, compared to analysts' expectations of $201.59 million. During the same quarter in the previous year, the company posted $0.26 EPS. The business's revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Sell-side analysts predict that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

About Repligen

(Free Report)

Repligen Corporation NASDAQ: RGEN develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company's offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.

Further Reading

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Repligen Right Now?

Before you consider Repligen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.

While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines